Skip to main content

A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers

Publication ,  Conference
Herold, C; Marcom, PK; Hopkins, J; McKeen, EA; Welch, RA; Chadaram, V; Spohn, J; Ung, C; Bacus, S; Peterson, BL; Blackwell, KL
Published in: CANCER RESEARCH
January 15, 2009

Duke Scholars

Published In

CANCER RESEARCH

ISSN

0008-5472

Publication Date

January 15, 2009

Volume

69

Issue

2

Start / End Page

238S / 239S

Location

San Antonio, TX

Publisher

AMER ASSOC CANCER RESEARCH

Conference Name

31st Annual San Antonio Breast Cancer Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herold, C., Marcom, P. K., Hopkins, J., McKeen, E. A., Welch, R. A., Chadaram, V., … Blackwell, K. L. (2009). A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers. In CANCER RESEARCH (Vol. 69, pp. 238S-239S). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
Herold, C., P. K. Marcom, J. Hopkins, E. A. McKeen, R. A. Welch, V. Chadaram, J. Spohn, et al. “A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers.” In CANCER RESEARCH, 69:238S-239S. AMER ASSOC CANCER RESEARCH, 2009.
Herold C, Marcom PK, Hopkins J, McKeen EA, Welch RA, Chadaram V, et al. A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers. In: CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2009. p. 238S-239S.
Herold, C., et al. “A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers.” CANCER RESEARCH, vol. 69, no. 2, AMER ASSOC CANCER RESEARCH, 2009, pp. 238S-239S.
Herold C, Marcom PK, Hopkins J, McKeen EA, Welch RA, Chadaram V, Spohn J, Ung C, Bacus S, Peterson BL, Blackwell KL. A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2009. p. 238S-239S.

Published In

CANCER RESEARCH

ISSN

0008-5472

Publication Date

January 15, 2009

Volume

69

Issue

2

Start / End Page

238S / 239S

Location

San Antonio, TX

Publisher

AMER ASSOC CANCER RESEARCH

Conference Name

31st Annual San Antonio Breast Cancer Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis